AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Article
December 11, 2019
Open Access

Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2

Raquel Ruiz-García, PhD https://orcid.org/0000-0002-8403-3613, Eugenia Martínez-Hernández, MD, PhD, Bastien Joubert, MD, Mar Petit-Pedrol, PhD, Elena Pajarón-Boix, MD, Verónica Fernández, MD, Lidia Salais, MD, María del Pozo, MD, Thais Armangué, MD, PhD, Lidia Sabater, PhD, Josep Dalmau, MD, PhD, and Francesc Graus, MD, PhDAuthors Info & Affiliations
March 2020 issue
7 (2)
https://doi.org/10.1212/NXI.0000000000000658
Letters to the Editor
Track CitationsAdd to favorites
Full Text HTML

Information & Authors

Information

Published In

Neurology® Neuroimmunology & Neuroinflammation
Volume 7 • Number 2 • March 2020
PubMed: 31826987

Copyright

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Publication History

Received: November 5, 2019
Accepted: November 18, 2019
Published online: December 11, 2019
Published in issue: March 2020

Permissions

Request permissions for this article.

Disclosure

R. Ruiz-Garcia, B. Joubert, E. Martínez-Hernánde, M. Petit-Pedrol, E. Pajarón-Boix, V. Fernández, L. Salais, M. del Pozo, T. Armangué, and L. Sabater report no disclosures. J. Dalmau receives royalties from Athena Diagnostics for the use of Ma2 as an autoantibody test and from Euroimmun for the use of NMDA, GABAB receptor, GABAA receptor, DPPX and IgLON5 as autoantibody tests. He is the editor of Neurology: Neuroimmunology & Neuroinflammation. F. Graus receives royalties from Euroimmun for the use of IgLON5 as an autoantibody test and honoraria for Assistant Editor of MedLink Neurology. Go to Neurology.org/NN for full disclosures.

Study Funding

This study was supported in part by Fondo de Investigaciones Sanitarias, FEDER, Spain (FIS 14/00203, J.D.; FIS 18/00067 L.S.), NIH RO1NS077851 (J.D.), and Fundació Cellex (J.D.). E. Martínez-Hernández is a recipient of a Juan Rodés grant (JR17/00012) from the Instituto de Salud Carlos III, Spain.

Authors

Affiliations & Disclosures

Raquel Ruiz-García, PhD https://orcid.org/0000-0002-8403-3613
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Eugenia Martínez-Hernández, MD, PhD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
JR17/00012: Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias, Madrid, Spain.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bastien Joubert, MD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mar Petit-Pedrol, PhD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Euroimmun
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Fondation Pierre Mercier pour la Science and Société Académique Vaudoise (Lausanne, Switzerland)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Elena Pajarón-Boix, MD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Verónica Fernández, MD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Lidia Salais, MD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
María del Pozo, MD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Thais Armangué, MD, PhD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
I received speaker honnoraria from Novartis (not related to this study)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
I received research support from Instituto Carlos III (PI18/00486) and Govern de la Generalitat de Catalunya (SLT006/17/00362)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
I received research support from Mutua Madrilena Fundation AP162572016 and La Marato de TV3 foundation (263/C/2014)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Lidia Sabater, PhD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Josep Dalmau, MD, PhD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate
Patents:
1.
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Advance Medical
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -ERA-NET Neuron
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun
Royalty Payments, Technology or Inventions:
1.
Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Francesc Graus, MD, PhD
From the Immunology Department (R.R.-G.), Centre Diagnòstic Biomèdic, Hospital Clínic; Neuroimmunology Program (E.M.-H., B.J., M.P.-P., T.A., L. Sabater, J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Service of Neurology (E.M.-H.), Hospital Clinic; Service of Neurology (E.P.-B., L. Salais), Hospital General de Castellón, Spain; Service of Pediatrics (V.F.), Hospital General de Albacete, Spain; Onco-Hematology Unit (M.d.P.), Service of Pediatrics, Hospital General de Albacete; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
member of the editorial Board of Lancet neurology since 2002 Associate Editor of MedLink Neurology
Patents:
1.
use of IgLON5 as a diagnostic test.
Publishing Royalties:
1.
Dr. Graus receives royalties from licensing fees to Euroimmun for the use of IgLON5 as a diagnostic test.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Graus [email protected]
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Yuan Xue,
    • Yi Guo,
    • Min Cheng,
    • Xiujuan Li,
    • Siqi Hong,
    • Li Jiang,
    • Wei Han,
    Overlapping syndrome with concomitant mGluR2-Ab and GFAP-Ab: A case report, Clinical Immunology, 277, (110508), (2025).https://doi.org/10.1016/j.clim.2025.110508
    Crossref
    • Ziyan Wu,
    • Siyuan Fan,
    • Honglin Xu,
    • Futai Feng,
    • Zhan Li,
    • Linlin Cheng,
    • Haolong Li,
    • Yongmei Liu,
    • Haoting Zhan,
    • Xinxin Feng,
    • Siyu Wang,
    • Shulan Zhang,
    • Yongzhe Li,
    Identifying Neurological Autoantibodies in COVID‐19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China, Journal of Medical Virology, 97, 5, (2025).https://doi.org/10.1002/jmv.70381
    Crossref
    • Hiroaki Yaguchi,
    • Akihiko Kudo,
    • Ichiro Yabe,
    Autoimmune cerebellar ataxia: An overlooked, but treatable, neuroimmune condition, Clinical and Experimental Neuroimmunology, (2025).https://doi.org/10.1111/cen3.70004
    Crossref
    • Yun Cai,
    • Zhijuan Hua,
    • Yanan Chen,
    • Xue Chen,
    • Na Liu,
    • Ting Liu,
    • Qianwen Zhou,
    • Jinghua Li,
    • Weiying Di,
    Clinical features of autoimmune cerebellar ataxia related to neuronal antibodies, Frontiers in Immunology, 16, (2025).https://doi.org/10.3389/fimmu.2025.1497695
    Crossref
    • Josep Dalmau,
    • Marinos C. Dalakas,
    • Dennis L. Kolson,
    • Anne-Katrin Pröbstel,
    • Friedemann Paul,
    • Scott S. Zamvil,
    Ten Years of Neurology® Neuroimmunology & Neuroinflammation, Neurology Neuroimmunology & Neuroinflammation, 12, 1, (2025)./doi/10.1212/NXI.0000000000200363
    Abstract
    • Ingeborg Viezens,
    • Ellen Knierim,
    • Hedwig E. Deubzer,
    • Kathrin Hauptmann,
    • Jessica Fassbender,
    • Susanne Morales-Gonzalez,
    • Angela M. Kaindl,
    • Markus Schuelke,
    • Marc Nikolaus,
    Expression of mGluR5 in Pediatric Hodgkin and Non-Hodgkin lymphoma—A Comparative Analysis of Immunohistochemical and Clinical Findings Regarding the Association between Tumor and Paraneoplastic Neurological Disease, Cancers, 16, 13, (2452), (2024).https://doi.org/10.3390/cancers16132452
    Crossref
    • Steven J. Frucht,
    • Pichet Termsarasab,
    • Steven J. Frucht,
    • Pichet Termsarasab,
    Ataxia, Movement Disorders Phenomenology, (567-641), (2024).https://doi.org/10.1007/978-3-031-52573-5_13
    Crossref
    • Claudia Papi,
    • Chiara Milano,
    • Marianna Spatola,
    Mechanisms of autoimmune encephalitis, Current Opinion in Neurology, 37, 3, (305-315), (2024).https://doi.org/10.1097/WCO.0000000000001270
    Crossref
    • Yahel Segal,
    • Anastasia Zekeridou,
    Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery, Current Opinion in Neurology, 37, 3, (295-304), (2024).https://doi.org/10.1097/WCO.0000000000001261
    Crossref
    • Christopher Hahn,
    • Adrian Budhram,
    • Katayoun Alikhani,
    • Nasser AlOhaly,
    • Grayson Beecher,
    • Gregg Blevins,
    • John Brooks,
    • Robert Carruthers,
    • Jacynthe Comtois,
    • Juthaporn Cowan,
    • Paula de Robles,
    • Julien Hébert,
    • Ronak K. Kapadia,
    • Sarah Lapointe,
    • Aaron Mackie,
    • Warren Mason,
    • Brienne McLane,
    • Alexandra Muccilli,
    • Ilia Poliakov,
    • Penelope Smyth,
    • Kimberly G. Williams,
    • Christopher Uy,
    • Jennifer A. McCombe,
    Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51, 6, (734-754), (2024).https://doi.org/10.1017/cjn.2024.16
    Crossref
  11. See more

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text HTML

View Full Text HTML
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF